Gsa Capital Partners LLP Cue Biopharma, Inc. Transaction History
Gsa Capital Partners LLP
- $1.32 Billion
- Q3 2024
A detailed history of Gsa Capital Partners LLP transactions in Cue Biopharma, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 291,663 shares of CUE stock, worth $460,827. This represents 0.02% of its overall portfolio holdings.
Number of Shares
291,663
Previous 277,559
5.08%
Holding current value
$460,827
Previous $344,000
35.76%
% of portfolio
0.02%
Previous 0.02%
Shares
16 transactions
Others Institutions Holding CUE
# of Institutions
53Shares Held
14.3MCall Options Held
14.4KPut Options Held
2.6K-
Bleichroeder LP New York, NY5MShares$7.9 Million1.28% of portfolio
-
Slate Path Capital LP New York, NY2.4MShares$3.8 Million0.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.03MShares$3.21 Million0.0% of portfolio
-
Black Rock Inc. New York, NY757KShares$1.2 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA509KShares$803,9460.0% of portfolio
About Cue Biopharma, Inc.
- Ticker CUE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,381,700
- Market Cap $55.9M
- Description
- Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...